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Abstract
Background: Phospholipid transfer protein (PLTP) is expressed by various cell types. In plasma, it is associated with high
density lipoproteins (HDL). Elevated levels of PLTP in transgenic mice result in decreased HDL and increased atherosclerosis.
PLTP is present in human atherosclerotic lesions, where it seems to be macrophage derived. The aim of the present study is
to evaluate the atherogenic potential of macrophage derived PLTP.
Methods and Findings: Here we show that macrophages from human PLTP transgenic mice secrete active PLTP.
Subsequently, we performed bone marrow transplantations using either wild type mice (PLTPwt/wt), hemizygous PLTP
transgenic mice (huPLTPtg/wt) or homozygous PLTP transgenic mice (huPLTPtg/tg) as donors and low density lipoprotein
receptor deficient mice (LDLR2/2) as acceptors, in order to establish the role of PLTP expressed by bone marrow derived
cells in diet-induced atherogenesis. Atherosclerosis was increased in the huPLTPtg/wtRLDLR2/2 mice (2.3-fold) and even
further in the huPLTPtg/tgRLDLR2/2 mice (4.5-fold) compared with the control PLTPwt/wtRLDLR2/2 mice (both
P,0.001). Plasma PLTP activity levels and non-HDL cholesterol were increased and HDL cholesterol decreased compared
with controls (all P,0.01). PLTP was present in atherosclerotic plaques in the mice as demonstrated by
immunohistochemistry and appears to co-localize with macrophages. Isolated macrophages from PLTP transgenic mice
do not show differences in cholesterol efflux or in cytokine production. Lipopolysaccharide activation of macrophages
results in increased production of PLTP. This effect was strongly amplified in PLTP transgenic macrophages.
Conclusions: We conclude that PLTP expression by bone marrow derived cells results in atherogenic effects on plasma
lipids, increased PLTP activity, high local PLTP protein levels in the atherosclerotic lesions and increased atherosclerotic
lesion size.
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Introduction
Phospholipid transfer protein (PLTP) is a plasma protein with
the capacity to transfer phospholipids between liposomes and
lipoproteins in vitro [1–4]. In addition, PLTP can also transfer
vitamin E [5] and is active as a conversion factor of high density
lipoproteins (HDL) [6,7]. HDL are generally considered anti-
atherogenic lipoproteins by virtue of their role in cholesterol
excretion (reverse cholesterol transport) [8], although other anti-
atherosclerotic properties of HDL have been described as well
[9,10]. Therefore, it was suggested that PLTP has a role in the
development of atherosclerosis, based on its relation with HDL
function [11,12]. In vivo, phospholipids become available for
PLTP-mediated transfer during lipolysis of triglyceride-rich
lipoproteins, mostly chylomicrons and very low density lipopro-
teins (VLDL), by the enzyme lipoprotein lipase [12]. The
phospholipids are transferred from triglyceride-rich lipoproteins
to HDL. PLTP is able to bind to and facilitate the transfer of
several types of phospholipids, including phosphatidylcholine,
phosphatidylethanolamine, and phosphatidylinositol, as well as
sphingomyeline [13]. In plasma, PLTP is mostly bound to HDL
[11].
In genetically modified mouse models the relation between the
activity levels of PLTP in plasma, HDL levels, HDL subclass
distribution and the development of atherosclerosis was studied in
more detail. We found that a 2.5-fold increased plasma PLTP
activity in transgenic mice resulted in a 30% decrease in plasma
HDL-cholesterol levels compared with wild type animals [14].
This represents total HDL, however. The formation of a specific
subfraction of HDL, termed preb-HDL, appeared to be increased
in plasma from transgenic mice. Although preb-HDL is a
quantitatively minor HDL subfraction, it is believed to be a very
efficient acceptor of cellular cholesterol and therefore an elevated
production of preb-HDL might result in a strong induction of
reverse cholesterol transport [15]. Therefore, we suggested that
PLTP increased the anti-atherogenic potential of HDL [14].
Subsequently Jiang and co-workers showed that PLTP deficiency
was anti-atherogenic, however [16], in spite of decreased levels of
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plasma HDL. The effect was attributed to a reduced production of
apolipoprotein (apo)B containing lipoproteins by the liver. Indeed,
we provided further evidence of an atherogenic role of PLTP in
studies in a series of PLTP transgenic mouse lines with increasing
levels of plasma PLTP activity, showing a PLTP-dose dependent
enhancement of atherosclerosis [17]. We also provided in vivo
evidence that PLTP is involved in the secretion of very low density
lipoproteins (VLDL) [17,18], but there was no PLTP-dose
dependent increase of this effect in the series of PLTP transgenic
mice tested [17]. In contrast, we observed a clear PLTP-dose
dependent reduction of plasma HDL levels in parallel to the
induction of atherosclerosis and therefore we concluded that
elevated plasma PLTP activity in transgenic mice is atherogenic
because it decreases plasma HDL. PLTP could also influence the
atherogenicity of plasma lipoproteins by decreasing the vitamin E
content of apoB-containing lipoproteins, resulting in increased
susceptibility for oxidation [19].
PLTP is expressed in a wide variety of cells and tissues in
humans [20], mice [21] and human PLTP transgenic mice [14].
In addition, the presence of PLTP in human atherosclerotic lesions
has been demonstrated [22,23], which probably originates from
macrophages. In order to elucidate the role of PLTP derived from
bone marrow derived cells, including macrophages, to atheroscle-
rosis, we performed in vitro studies with macrophages from PLTP
transgenic mice and performed bone marrow transplantations
from PLTP transgenic mice to low density lipoprotein (LDL)
receptor deficient mice and subsequently studied the process of
diet-induced atherosclerosis as influenced by these bone marrow
transplantations.
Methods
Mice
LDLR2/2 mice were obtained from the Jackson Laboratory
(Bar Arbor, ME) and were in C57BL6/J background. Mice
expressing enhanced green fluorescent protein (EGFP) under the
control of the chicken beta-actin promotor and cytomegalovirus
enhancer were originally generated by Okabe et al. and were in
C57BL6/J background [24,25]. Human PLTP transgenic mice
were generated in our laboratory as described before and are
derived from the P4 line [17]. The transgene in these animals
contains the complete human PLTP gene, including approxi-
mately 15 kb 59 natural flanking region and 3 kb 39 natural
flanking region. The transgene is driven by its autologous human
promoter. PLTP transgenic mice were crossbred to C57BL6/J
background for .15 generations. Subsequently, homozygous
PLTP transgenic mice were obtained by crossbreeding hemizy-
gous PLTP transgenic mice. Animals were provided with food and
water ad libitum. Food was either regular chow, or a high fat, high
cholesterol diet containing 40% (w/w) sucrose, 15% (w/w) cocoa
butter, and 0.25% (w/w) cholesterol (diet W; Hope Farms,
Woerden, The Netherlands). The numbers of animals used for
measurements are indicated in the Figure legends. Only male mice
were used. All of the procedures in this study were in accordance
with national and institutional guidelines.
Bone marrow transplantation
On the day of donor cell injection, LDLR2/2 mice of 12 weeks
old were conditioned by 900 rads of c-irradiation from a 137Cs
source, which was administered in a split dose, with a 3 hours
interval. Cells were injected i.v. into the tail veins. Each recipient
received 56 106 bone marrow cells isolated from the femurs and
tibias of the primary donors. Injected animals were provided with
0.16% Neomycin (Sigma-Aldrich)-supplemented water. Animals
were kept on a regular chow diet until 9 weeks after transplantation.
During the next 9 weeks, animals were fed a high fat, high
cholesterol diet.
Analysis of plasma lipids, lipoproteins, PLTP
concentration and PLTP activity
Blood samples were obtained via orbital bleedings after an
overnight fast at 1 week before the bone marrow transplantation,
just before the start of the diet and at the end of the 9 weeks high
fat, high cholesterol diet feeding. Plasma lipids (total cholesterol,
phospholipids and triglycerides) were measured using commer-
cially available kits (Wako Chemicals). Lipoprotein fractions were
obtained by ultracentrifugation of plasma samples in a Beckman
42.2 Ti rotor (42000 rpm, 3 h, 12uC) at d = 1.063 g/ml. Tubes
were sliced, and two fractions were collected: non-HDL
(VLDL+LDL), d,1.063 g/ml; and HDL, d.1.063 g/ml. PLTP
activity in plasma was measured as described previously [14] and
expressed in arbitrary units (AU). 1 AU is equivalent to the activity
found in human reference plasma, which is 14 mmol/ml/h. PLTP
concentration was measured by ELISA as described [18], using
PLTP antibodies which were kindly donated by Dr. H. Hattori
(BML Incorporated, Saitama, Japan). PLTP specific activity was
calculated as the ratio (PLTP activity in AU)/(human PLTP
concentration in mg/L).
Histological analyses and quantification of
atherosclerotic lesions
Animals were anesthetized using isoflurane, and in situ fixation
was performed via the left ventricle of the heart using phosphate-
buffered formaldehyde (4%, v/v). Sectioning of the aortic root,
hematoxilin/eosin staining, the collection of digital images and the
quantification of atherosclerotic lesions were performed as
described before [26].
Immunohistochemistry was performed using antibodies directed
against CD68 to detect macrophages (AbD Serotec, Kidlington,
UK), against CD31 to detect endothelial cells (Hycult Biotech-
nology BV, Uden, The Netherlands), or against vascular smooth
muscle cells alpha-actin (Sigma Chemical Co., Zwijndrecht, The
Netherlands) or against PLTP (kind gift of Dr. Matti Jauhiainen,
Helsinki, Finland).
Cell culture studies
For the isolation of primary macrophages mice were i.p.
injected with 3 mL of 40.5 g/L BactoH Brewer Thioglycollate
Medium (Difco International B.V., Leeuwarden, The Nether-
lands). After three days the animals are anesthetized using
isoflurane and macrophages are isolated from the peritoneal
cavity in 0.34 M sucrose. Cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM, Gibco, Invitrogen, Breda, The
Netherlands) supplemented with 10% (v/v) fetal bovine serum and
100 U/mL penicillin/streptomycin. Cells were seeded on 6 wells
plates (36106 cells/well) and kept in culture for 24 hours.
Alternatively, macrophages derived from bone marrow in vitro
were obtained by isolating bone marrow cells from tibias and
femurs, seeding the cells on 6-wells plates (36105 cells/well) and
culturing them in the presence of 10 ng/ml Macrophage Colony
Stimulating Factor (Biosource International, Camarillo CA, USA)
[27]. The concentrations of TNF-a, IFN-c, IL-4, or IL-10 in the
supernatants were measured using commercially available ELISAs
(BD Biosciences Pharmingen, Alphen aan den Rijn, The Nether-
lands). PLTP activity was measured after 24 hours of culture in the
supernatant with the same assay as used for the PLTP activity
measurements in plasma. In some cases, cells were challenged by
Macrophage PLT
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adding 100 ng/mL bacterial lipopolysaccharide (from E. coli
serotype 0111:B4, Sigma, Chemical Co., Zwijndrecht, The
Netherlands). In order to measure the cholesterol loading and
efflux capacity [28], macrophages were seeded on 3 cm dishes
(36106 cells/dish). After 2 hours, the medium was replaced with
DMEM supplemented with 1% (v/v) fetal bovine serum, 100 U/mL
penicillin/streptomycin, 30 mg/mL acetylated LDL (acLDL) [29],
1 mg/mL Acyl CoA:cholesterol acyltransferase inhibitor (gift from
Sandoz AG, Basel, Switzerland) and 0.33 mCi [3H]-cholesterol/mL
for 22 hours. Efflux was monitored by incubating these loaded cells
in DMEM containing 0.2% (w/v) fat-free BSA (Sigma Chemical
Co., #6003, Zwijndrecht, The Netherlands) and 100 mg/mL
human HDL and sampling the medium at 1, 2, 4, and 6 hours.
At the end of the efflux study, cell associated radioactive cholesterol
was measured and the percentage of cholesterol efflux was
calculated. Cells were lysed in 0.1 M NaOH/ 0.5% (w/v) SDS
and cellular protein was determined using the Lowry method [30].
Statistics
All of values are expressed as mean6S.E. Statistical analyses are
by one-way analysis of variance with Bonferroni multiple
comparison tests performed with Intercooled Stata 6.0 software
(Stata Corp., College Station, TX, USA).
Results
PLTP production by mouse macrophages
In a first set of experiments, peritoneal macrophages were
collected from three groups of mice: wild type control animals
(PLTPwt/wt), hemizygous human PLTP transgenic mice
(huPLTPtg/wt) and homozygous human PLTP transgenic mice
(huPLTPtg/tg). Macrophages were kept in culture for 24 hours
before PLTP activity was measured in the culture medium. As
shown in Fig. 1, PLTP activity could be measured in the medium
of cells from PLTPwt/wt mice, demonstrating that PLTP is
produced and excreted by macrophages. When macrophages
from huPLTPtg/wt and huPLTPtg/tg mice were tested, increased
PLTP activity was found (+125% and +233%, respectively, both
p,0.01). From these results we conclude that macrophages from
transgenic PLTP mice have an increased production and secretion
of the transgenic protein.
Effects of bone marrow transplantation on plasma PLTP
activity
In order to study the contribution of PLTP expression by bone
marrow derived cells on plasma PLTP activity, we performed bone
marrow transplantation experiments from PLTPwt/wt, huPLTPtg/wt
and huPLTPtg/tg mice to lethally irradiated LDL-receptor deficient
(LDLR2/2) mice. Following the transplantation, animals were
allowed to recover for 9 weeks. Subsequently, animals were fed a
high fat, high cholesterol diet for another 9 weeks period. Blood
samples were collected one week before irradiation, just before
starting the diet and at the end of the 9 weeks diet period (time points
-10 weeks, 0 weeks and 9 weeks, relative to the start of the diet,
respectively). In addition to the transplanted animals, groups of
LDLR2/2 mice and LDLR2/2/huPLTPtg/wt mice were subjected
to the same series of experiments, except the irradiation and bone
marrow transplantation. Blood samples were collected at 0 weeks
and 9 weeks. Animals were age matched to the mice in the
transplantation groups.
As shown in Fig. 2A (left panel), plasma PLTP activity in
LDLR2/2/huPLTPtg/wt mice were approximately 3-fold higher
than in LDLR2/2 mice when fed a chow diet (0 weeks). After
feeding the animals a high fat, high cholesterol diet for 9 weeks,
plasma PLTP activity in both LDLR2/2 and LDLR2/2/
huPLTPtg/wt mice was increased by about 2-fold when compared
to chow fed animals of the same genotype.
Fig. 2A (right panel) also shows the plasma PLTP activity in
transplanted animals. The transplantation procedure itself resulted
in a significant increase in PLTP activity, ranging from 29% in the
PLTPwt/wtRLDLR2/2 mice to 88% in the huPLTPtg/tgR
LDLR2/2 mice (all p,0.001). After feeding the animals a high
fat, high cholesterol diet, a further increase in plasma PLTP activity
was observed ranging from 82% in the PLTPwt/wtRLDLR2/2mice
to 113% in the huPLTPtg/tgRLDLR2/2mice (all p,0.001). Under
both dietary conditions, plasma PLTP activity did not differ between
huPLTPtg/wtRLDLR2/2 and huPLTPtg/tgRLDLR2/2 mice.
Fig. 2B shows the concentration of human PLTP in plasma
from transplanted animals. As there is no ELISA available for
mouse PLTP, mass of plasma PLTP could only be measured in the
huPLTPtg/wtRLDLR2/2 and huPLTPtg/tgRLDLR2/2 mice.
The PLTP concentration appeared to be approximately twice as
much in the latter animals. The high fat, high cholesterol diet
resulted in a two-fold increase in PLTP mass. The specific activity
of plasma PLTP was not affected by the diet (Fig. 2C).
Interestingly however, the specific activity in the huPLTPtg/tgR
LDLR2/2 mice was significantly lower than in the huPLTPtg/wt
RLDLR2/2 mice, implying that part of the huPLTP in the
huPLTPtg/tgRLDLR2/2 mice is in the inactive form.
Effects of bone marrow transplantation on plasma lipids
and lipoproteins
When fed a regular chow diet, plasma cholesterol levels were
slightly decreased in LDLR2/2/huPLTPtg/wt mice when com-
pared to LDLR2/2 mice (Fig. 3A, left panel). However, this
difference was absent after feeding the animals a high fat, high
cholesterol diet for 9 weeks. In the transplanted animals, no major
differences in plasma cholesterol concentration were observed
between the various groups on chow diet (Fig. 3A, right panel).
However, after feeding the animals a high fat, high cholesterol diet
for 9 weeks an increase in cholesterol concentration was observed
in PLTPwt/wtRLDLR2/2, huPLTPtg/wtRLDLR2/2, and
huPLTPtg/tgRLDLR2/2 mice. Effects on plasma phospholipids
and triglycerides largely mirrored those on plasma cholesterol
(Fig. 3B,C). In order to further investigate these differences, HDL
Figure 1. PLTP production by mouse macrophages. Peritoneal
macrophages were collected from either C57BL/6J wild type (wt/wt),
hemizygous huPLTP transgenic (tg/wt) and homozygous huPLTP
transgenic (tg/tg) mice and kept in culture for 24 hours. Subsequently,
PLTP activity was measured in a sample of the culture medium. PLTP
activity is expressed as arbitrary units (AU; 1 AU is equivalent to
14 mmol/mL/h). N = cells from 6 mice per group. ** p,0.005 versus wt/
wt; $ p,0.01 versus tg/wt.
doi:10.1371/journal.pone.0002255.g001
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and non-HDL was separated in plasma samples of the animals
after 9 weeks on a high fat, high cholesterol diet. The mice
transplanted with huPLTP transgenic bone marrow cells showed
an increase in non-HDL cholesterol (Fig. 4A) and a decrease in
HDL-cholesterol (Fig. 4B) when compared with the mice
transplanted with wild type bone marrow cells.
Effects of bone marrow transplantation on
atherosclerosis
After feeding the animals a high fat, high cholesterol diet for 9
weeks, atherosclerosis was quantified by measuring the area of
atherosclerotic lesions in the aortic root. In agreement with
previous studies from our laboratory [17,31], we found that
Figure 2. Plasma PLTP levels. A. PLTP activity was measured in plasma samples and expressed in arbitrary units as described in the legend of
Fig. 1. Left panel: plasma samples were collected from non-transplanted LDLR2/2 and LDLR2/2/huPLTPtg/wt mice just before the start of the high fat,
high cholesterol diet (0 weeks, white bars) and after 9 weeks of the diet (9 weeks, black bars). *** p,0.001 versus 0 weeks (same genotype), ###
p,0.001 versus LDLR2/2 mice (on the same diet). Right panel: plasma samples were collected from PLTPwt/wtRLDLR2/2, huPLTPtg/wtRLDLR2/2, and
huPLTPtg/tgRLDLR2/2 recipient mice at 1 week before the start of the transplantation procedure (i.e. at 10 weeks before the start of the diet: 210
weeks, grey bars), just before the start of the diet (0 weeks, white bars) and after 9 weeks of diet (9 weeks, black bars). *** p,0.001 versus210 weeks
(same genotype); ### p,0.001 versus PLTPwt/wtRLDLR2/2 mice (on the same diet); """ p,0.001 versus 0 weeks (same genotype). B. Mass of
human PLTP in plasma from mice was measured by ELISA as described in Methods in the Supplemental Data. C. Specific Activities of PLTP were
calculated using the ratio between the activity in AU and the mass in mg/L. """ p,0.001 versus 0 weeks (same genotype); $$$ p,0.001 versus
PLTPtg/wtRLDLR2/2 mice (on the same diet). N = 11–15 mice per group.
doi:10.1371/journal.pone.0002255.g002
Macrophage PLT
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elevated levels of PLTP result in a strong increase (312%) in diet-
induced atherosclerosis in non-transplanted mice (Fig. 5A, left
panel; p,0.001). In transplanted mice, a clear increase in
atherosclerotic lesion area was observed (Fig. 5A, right panel; all
differences p,0.001). Compared to PLTPwt/wtRLDLR2/2 mice,
huPLTPtg/wtRLDLR2/2 mice have an increase of 128% in
atherosclerotic lesion area, while huPLTPtg/tgRLDLR2/2 mice
have an increase of 348% in atherosclerotic lesion area.
The presence of PLTP expressing macrophages in the aortic
lesions was confirmed by immunohistochemistry. As illustrated in
Fig. 5, the plaques from both non-transplanted LDLR2/2/
huPLTPtg/wt mice (Fig. 5B) as those from recipient huPLTPtg/tg
RLDLR2/2 mice (Fig. 5C) contain considerable amounts of
macrophages while PLTP is co-localized in similar areas of the
lesions.
In order to be more conclusive on the nature of the bone
marrow derived cells, we performed an additional set of
experiments using actin-EGFP mice as donors and LDLR2/2
mice as acceptors, using exactly the same experimental procedure
to obtain diet-induced atherosclerosis. Sections from the aortic
root were inspected using confocal microscopy after immunohis-
tochemistry with antibodies directed against CD68 as a marker for
macrophages or VSMC a-actin as a marker for VSMCs. DAPI
staining was used to visualize nuclei. Bone marrow derived donor
cells, identified by the GFP signal, are clearly present in the
Figure 3. Plasma lipid levels. Plasma levels of cholesterol (A),
phospholipids (B) and triglycerides (C) were measured as described in
Methods. Left panels: Plasma samples were collected from non-
transplanted LDLR2/2 and LDLR2/2/huPLTPtg/wt mice just before the
start of the high fat, high cholesterol diet (0 weeks, white bars) and after
9 weeks of the diet (9 weeks, black bars). *** p,0.001 versus 0 weeks
(same genotype), ### p,0.001 versus LDLR2/2 mice (on the same
diet). Right panels: plasma samples were collected from PLTPwt/wt
RLDLR2/2, huPLTPtg/wtRLDLR2/2, and huPLTPtg/tgRLDLR2/2 recipi-
ent mice at 1 week before the start of the transplantation procedure
(i.e. at 10 weeks before the start of the diet: 210 weeks, grey bars), just
before the start of the diet (0 weeks, white bars) and after 9 weeks
of diet (9 weeks, black bars). N = 11–15 mice per group. * p,0.05,
*** p,0.001 versus 210 weeks (same genotype); ### p,0.001 versus
PLTPwt/wtRLDLR2/2 mice (on the same diet).
doi:10.1371/journal.pone.0002255.g003
Figure 4. Plasma levels of non-HDL cholesterol and HDL
cholesterol. Plasma was collected from PLTPwt/wtRLDLR2/2,
huPLTPtg/wtRLDLR2/2, and huPLTPtg/tgRLDLR2/2 recipient mice at
the end of the high fat, high cholesterol diet period (i.e., at time of
sacrifice) and separated into two fractions: d,1.063 g/L (non-HDL) and
d.1.063 g/L (HDL) by ultracentrifugation. In both fractions, the
cholesterol concentration was measured. A: non-HDL cholesterol; B:
HDL-cholesterol. N = 11–15 mice per group. ** p,0.01, *** p,0.001
versus PLTPwt/wtRLDLR2/2 mice; $$$ p,0.001 versus huPLTPtg/wt
RLDLR2/2 mice.
doi:10.1371/journal.pone.0002255.g004
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subendothelial space of the early lesions and co-localize to a great
extent with CD68 (Fig. 6A,B). In the advanced lesions, the cell-rich
regions show significant co-localization of the GFP and CD68
signals, while the necrotic core stills allows detection of CD68, but
GFP is no longer expressed (Fig. 6C,D). In early lesions, VSMCs
are almost exclusively located in the media (Fig. 6B). In advanced
lesions, VSMCs can be detected in the fibrous cap (Fig. 6D), but
they do not co-localize with GFP, demonstrating that also the
VSMCs in the lesions are not donor-derived. As shown in Fig. 6A–
D, isolated nuclei can be detected of endothelial cells covering the
lesions without GFP signal, demonstrating that these cells are not
donor-derived. Positive staining for endothelial cells was per-
formed by using an antibody directed against CD31 (Fig. 6E,F).
The endothelial lining in early (Fig. 6E) and in advanced (Fig. 6F)
lesions is continuous and does not express GFP, implying that the
endothelial cells are not donor derived.
Characterization of PLTP expressing macrophages
In order to investigate the mechanism by which mice
transplanted with bone marrow cells expressing elevated levels of
PLTP develop more atherosclerosis, we performed a series of in
vitro studies using primary macrophages from PLTPwt/wt,
huPLTPtg/wt, and huPLTPtg/tg mice, respectively.
First we examined whether PLTP expression in macrophages
affects their capacity to perform cellular cholesterol efflux. To this
end, macrophages were loaded with radiolabeled cholesterol using
acLDL and efflux to the medium was studied during six hours
using human HDL as an acceptor. There was no difference in
cholesterol loading between macrophages from PLTPwt/wt and
huPLTPtg/tg mice (42.87+/28.25 versus 44.26+/28.67%
[3H]cholesterol/mg cell protein). No difference in efflux to HDL
was observed (Fig. 7A). Consequently, the amount of radioactive
cholesterol that remained cell-associated at the end of the efflux
period was also similar (not shown).
Possible differences between the inflammatory status of the
macrophages were studied by comparing the level of the cytokines,
TNF-a, IFN-c, IL-4, and IL-10, by ELISA. No differences were
found in medium from macrophages obtained from PLTPwt/wt,
huPLTPtg/wt, and huPLTPtg/tg mice before or after stimulation with
LPS (results not shown). These results indicate that there is no
difference in cytokine production by macrophages from these mice.
Subsequently, we studied whether activated macrophages have
different PLTP activity. Therefore, we challenged the macro-
phages with bacterial lipopolysaccharide (LPS), and measured
PLTP activity in the medium from the stimulated macrophages.
As shown in Fig. 7B, stimulation of macrophages from PLTPwt/wt
mice with LPS resulted in approximately 70% increase in PLTP
activity. Unstimulated macrophages from huPLTPtg/wt or
huPLTPtg/tg mice secreted approximately 2.5 to 4 fold more
PLTP in the culture medium than macrophages from PLTPwt/wt
mice. LPS stimulation resulted in a further 7.5 fold increase of
PLTP activity in the culture medium from macrophages from
huPLTPtg/wt or huPLTPtg/tg mice. In order to investigate whether
this in vitro effect would be reflected by similar effects in vivo, we
measured plasma PLTP activity levels in both PLTPwt/wt and
huPLTPtg/tg mice that were treated with thioglycolate. In both
cases, this treatment resulted in a statistically significant (P,0.002)
increase in plasma PLTP activity (Fig. 7C).
Finally, we cultured macrophages from bone marrow in order
to consolidate these findings. Comparing macrophages from
PLTPwt/wt and huPLTPtg/tg mice, we found much more PLTP
activity in the medium of the huPLTPtg/tg cells. PLTP activity
could be significantly increased in cells from both PLTPwt/wt and
huPLTPtg/tg mice after treatment with LPS (not shown).
Discussion
The main findings of this study are: (1) Mouse macrophages
express and secrete PLTP while mouse macrophages from human
PLTP transgenic mice express and secrete increased levels of
PLTP; (2) Bone marrow transplantations using PLTP transgenic
mice as donors induce elevated plasma PLTP activity levels in the
acceptor mice; (3) PLTP overexpression results in decreased
plasma levels of HDL cholesterol and in increased plasma levels of
non-HDL cholesterol; (4) Transplantation with PLTP expressing
bone marrow cells results in increased (2–4.5 fold) atherosclerosis
with abundant intra-plaque presence of PLTP.
Figure 5. Atherosclerosis in non-transplanted and transplanted
mice. A. Plaque area was measured in sections from the aortic root (see
Methods). Left panel: Plaque area in non-transplanted LDLR2/2 and
LDLR2/2/huPLTPtg/wt mice. *** p,0.001 versus LDLR2/2 mice. Right
panel: Plaque area in PLTPwt/wtRLDLR2/2, huPLTPtg/wtRLDLR2/2,
and huPLTPtg/tgRLDLR2/2 recipient mice. N= 11–15 mice per group.
*** p,0.001 versus PLTPwt/wtRLDLR2/2 mice; $$$ *** p,0.001 versus
huPLTPtg/wtRLDLR2/2 mice. B, C. Immunohistochemistry of athero-
sclerotic lesions from non-transplanted LDLR2/2/huPLTPtg/wt mice (B)
and from transplanted huPLTPtg/tgRLDLR2/2 mice (C), stained for
macrophages (MW) with anti-CD68 and for PLTP and counterstained
with Nuclear-fast red (serial sections). The right panels are magnifica-
tions of the boxed parts in the left panels. Original magnifications: 100x
(B) and 250x (C).
doi:10.1371/journal.pone.0002255.g005
Macrophage PLT
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The potential relevance of PLTP production by macrophages is
emphasized by three independent studies, showing that PLTP
protein is present in human atherosclerotic lesions [22,23,32].
Although intriguing, the presence of PLTP in atherosclerotic
lesions per se does not prove a direct involvement in the process of
atherosclerosis and therefore the significance of these findings is
unclear. In humans, the causal relation between PLTP and
atherosclerosis is still uncertain [33]. Plasma PLTP activity is
elevated in patients suffering from diabetes mellitus type 1 [34]
and type 2 [35,36]. In addition, increased PLTP is found in obese
individuals [37–40] while it is decreased with weight loss [41]. The
elevated plasma PLTP activity in patients with type 2 diabetes
mellitus is positively correlated with the carotid intima-media
thickness [42].
In order to find out what the contribution of PLTP expressing
macrophages to diet induced atherosclerosis would be, we
performed bone marrow transplantation experiments.
9 weeks after bone marrow transplantation, a moderate increase
in plasma PLTP activity was found in the animals transplanted
with PLTPwt/wt cells. In the animals transplanted with PLTP
transgenic cells, a further increase was observed. Feeding the
animals a high fat, high cholesterol diet for 9 weeks, resulted in a
Figure 6. Transplantations with b-actin GFP miceRLDLR2/2 mice. A–D: Early lesions (A,B) and advanced lesions (C,D) with donor cells
expressing GFP (green), CD 68 (marker for macrophages) in red (A,C) and a-actin (marker for VSMCs) in red (B,D) and nuclei stained with DAPI (blue).
Endothelial cells covering the lesions do not express GFP (nuclei indicated with arrows). Co-localization of GFP and CD68 results in an orange color
(arrowheads). The necrotic core in the advanced lesion (located centrally in C and D) is diffusely positive for CD68 but does not show any GFP signal.
The media is marked with a double arrow («). E,F: Early lesion (E) and advanced lesion (F) with donor cells expressing GFP (green), and CD 31 (marker
for endothelial cells) in red (arrows). Representative pictures from N=6 animals are shown. Original magnifications: 200X.
doi:10.1371/journal.pone.0002255.g006
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striking increase in plasma PLTP activity. It has been demon-
strated that cholesterol loading of macrophages induces a strong
(2–3 fold) induction of PLTP mRNA, PLTP protein secretion and
an increased PLTP activity in the medium conditioned by these
cells [23,32]. Our results show that in animals fed a high fat, high
cholesterol diet, plasma from huPLTPtg/wtRLDLR2/2 and
huPLTPtg/tgRLDLR2/2 mice have a 66–75% increase in PLTP
activity when compared to plasma from PLTPwt/wtRLDLR2/2
mice. Thus we conclude that a considerable amount of
macrophage PLTP is excreted into the blood.
An increase in plasma PLTP activity affects plasma lipids. Plasma
cholesterol is not affected by the moderate increase in PLTP activity
caused by the bone marrow transplantation procedure itself. After 9
weeks of high fat, high cholesterol diet plasma cholesterol is elevated,
as expected, but a further increase is observed in the huPLTPtg/
wtRLDLR2/2 and huPLTPtg/tgRLDLR2/2 mice. So, PLTP
expression by bone marrow derived cells affects not only plasma
PLTP activity levels, but also plasma lipids.
Because PLTP activity can be directly measured in plasma, our
experiments clearly show that PLTP is excreted by bone marrow
derived cells into the plasma compartment. Probably this is the
cause of the observed decrease in plasma HDL cholesterol, which
is in agreement with previous results from our laboratory
[14,17,31] and others [43,44], and which is probably caused by
an enhanced catabolism of HDL [43]. Most likely, this effect will
contribute to the observed enhanced atherosclerosis in mice
transplanted with huPLTP transgenic bone marrow. In addition
however, there might be a local effect of PLTP produced by
macrophages in the vascular wall. Although PLTP overexpressing
macrophages do not show any difference in cholesterol efflux
capacity or cytokine production, a very strong induction of PLTP
production is observed in macrophages treated with LPS. So,
activated macrophages present in the inflammatory environment
of atherosclerotic plaques probably excrete large amounts of
PLTP. This is confirmed by immunohistochemistry data in the
present study. The high local PLTP production might result in a
further increase of the inflammatory status of the lesions.
Additional support for this idea is provided by studies showing
that PLTP deficiency is associated with anti-inflammatory effects
[45,46], and by a study in which an association was found between
PLTP activity and inflammatory markers in patients with
cardiovascular disease [47]. Alternatively, extracellular PLTP
might act as a trap for HDL. PLTP is able to bind to the
extracellular matrix proteoglycan biglycan [23] and thus act as a
bridging molecule to bind HDL. In vitro studies showed that this
action is independent of PLTP’s phospholipid transfer activity. By
trapping HDL in the atherosclerotic lesion, PLTP could interfere
with the reverse cholesterol transport activity of HDL and thus
enhance lipid accumulation, or actually, inhibit lipid removal, and
hence stimulate the development of the plaque. It is uncertain
whether this HDL retention may contribute to the decreased
plasma levels of HDL observed in mice transplanted with huPLTP
transgenic bone marrow.
While macrophage expression of PLTP has both systemic and
local effects, both of which might be atherogenic, the steep
increase in atherosclerotic lesion size of almost 2-fold between
Figure 7. Characteristics of mouse macrophages. A. Cholesterol
efflux from cultured peritoneal macrophages. Cells were loaded with
radioactive cholesterol as described in Methods. Subsequently, culture
medium with human HDL as an acceptor was added. Left panel:
Radioactivity was measured in aliquots from the cultured medium taken
at 0, 1, 2, 4, and 6 hours. Circles: macrophages from C57BL/6J mice,
squares: macrophages from huPLTPtg/tg mice. Differences were not
statistically significant. B. PLTP activity measured in the medium of
macrophages cultured for 24 hours in the absence (white bars) or
presence (black bars) of 100 ng/mL LPS. Cells from 6 mice were used
per group. C. PLTP activity measured in plasma samples from mice
treated with thioglycolate. N= 6 mice per group. ** p,0.005, ***
p,0.001 versus cells without LPS or thioglycolate (same genotype),##
p,0.005, ### p,0.001 versus PLPTwt/wt (same culture medium, with
or without LPS or thioglycolate).
doi:10.1371/journal.pone.0002255.g007
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huPLTPtg/wtRLDLR2/2 and huPLTPtg/tgRLDLR2/2 mice is
not completely reflected by the differences in the systemic effects, as
these mice have similar plasma PLTP activities. This suggests that
local effects of PLTP expression might indeed play an important
role. In addition, the huPLTPtg/tgRLDLR2/2mice show a reduced
specific activity of PLTP. This could indicate that the huPLTPtg/tg
RLDLR2/2 mice have relatively more inactive PLTP [48], which
may not have phospholipids transfer activity, but which might still
have some of the other effects described above. Also, PLTP secreted
by the huPLTPtg/tg bone marrow derived cells in the transplanted
animals finds itself in a plasma environment with very little HDL. As
active PLTP is normally bound to HDL, this situation could
destabilize PLTP resulting in partial PLTP inactivation and in a
decrease in PLTP specific activity.
It should be noted that bone marrow derived cells include cells
other than macrophages, like endothelial cells and VSMCs.
Therefore, we performed a set of control experiments with b-actin
GFP donor mice. It became clear that using our experimental
conditions, the contribution from bone marrow derived endothe-
lial cells or VSMCs to the atherosclerotic lesion is undetectable,
while there is a significant number of bone marrow derived
macrophages in the lesions.
Recently, the susceptibility to diet-induced atherosclerosis was
studied in mice after bone marrow transplantations with bone
marrow cells from wild type and PLTP deficient mice. Strikingly
different results were reported by two independent research
groups, leading to opposite conclusions [49,50]. While Valenta et
al [49] propose an athero-protective role for macrophage derived
PLTP, Vikstedt et al [50] show evidence for an atherogenic
function of macrophage derived PLTP. Both groups used
LDLR2/2 mice as acceptors, and either wild type or PLTP2/2
mice as donors. All mice had the same genetic background
(C57BL/6J), and the same strain of PLTP deficient mice were
used. When comparing mice transplanted with PLTP2/2 bone
marrow with mice transplanted with wild type bone marrow,
Valenta et al found an increase in atherosclerotic lesion area in of
30% (measured in the aortic valves) or 28% (measured in the entire
aorta), while Vikstedt et al found a decrease of 29% (measured in the
aortic valves). In both studies, plasma PLTP activity is lower in mice
transplanted with PLTP2/2 bone marrow than in mice transplanted
with wild type bonemarrowwhen fed a chow diet, and the difference
becomes larger in mice fed an atherogenic diet. In the study by
Vikstedt et al this leads to a significant decrease in plasma cholesterol
levels and an increase in HDL, which may explain the decreased
atherosclerosis found in mice transplanted with PLTP2/2 bone
marrow. In the study by Valenta et al there is increased
atherosclerosis while plasma cholesterol levels are hardly changed.
Thus, in the latter study postulated that plasma PLTP is atherogenic,
while PLTP which is locally active in the vascular wall may have
anti-atherogenic potential, possibly by local stimulation of macro-
phage cholesterol efflux.
Vikstedt et al have summarized the major differences in
experimental set-up: 1) Vikstedt et al used female mice as
acceptors while Valenta et al used male mice; 2) Vikstedt et al
fed the mice an atherogenic diet with 0.25% cholesterol for 9
weeks while the diet used by Valenta et al contained 1.25%
cholesterol and was fed for 16 weeks; 3) Vikstedt et al allowed the
mice to recover from the bone marrow transplantation procedure
for 8 weeks before the atherogenic diet was supplied while Valenta
et al applied a recovery time of only 4 weeks. Vikstedt et al do not
indicate if any of these differences could be the deciding factor to
explain the different outcomes of their studies.
Very recently, Valenta et al confirmed their previous findings in
a study in which they used LDLR2/2/PLTP2/2 mice as
acceptors [51]. Here, they applied the same experimental set-up
as in their earlier work. In the discussion of this recent paper, the
differences with the experimental set-up followed by Vikstedt et al
are listed, but there are no conclusions about what might really
cause the different outcomes.
We believe that the difference in gender between the recipients
in the studies using PLTP deficient mice is not a likely explanation
for the conflicting results. Although it is well-known that the
susceptibility of female and male mice to atherosclerosis is
different, the reason for this phenomenon is unknown, and, to
the best of our knowledge, there are no reports where opposite
outcomes of an intervention with respect to atherosclerosis
susceptibility between males and females have been described.
In fact, we have shown in a previous study that in animals with
elevated PLTP activity, both males and females have more
atherosclerosis [52].
The difference in diet-regime may be an essential factor. The
diet used by Valenta et al contains five times as much cholesterol
as the diet used by Vikstedt et al and was applied much longer.
Therefore, this is a significantly more aggressive way of induction
of atherosclerosis. It is conceivable that this has affected the
outcome of the study.
The difference in recovery time may be an essential factor as well.
Vikstedt et al allowed the animals to recover for eight weeks,
compared to four weeks in the study of Valenta et al. Four weeks is
really a very short time, in which the hematopoietic system has not
yet been stably reconstituted. It is conceivable, that PLTP deficiency
affects the repopulation of monocytes/macrophages. Therefore, the
development of atherosclerotic lesions may be affected by differences
in recovery time. Also, the reconstitution of resident macrophages in
lung and liver, both important sites of PLTP expression, may not yet
be stable after only four weeks of recovery [53].
We studied the effects of elevated PLTP expression using
transgenic mouse models that have been developed in our own
laboratory. The interpretation of our results is independent from
the conflicting results that have been reported using PLTP2/2
mice. Our experimental set-up is comparable to the one used by
Vikstedt et al, as we also fed the mice a diet containing 0.25%
cholesterol for 9 weeks, and we used an even slightly longer
recovery period (9 weeks). Their results are in line with our
findings, as we report an increase of atherosclerosis in mice
transplanted with PLTP overexpressing bone marrow, while they
found decreased atherosclerosis in mice transplanted with
PLTP2/2 bone marrow cells.
In conclusion, we showed that elevated macrophage expression
of PLTP results in increased atherosclerosis. This is probably
directly related to the effects on plasma lipoproteins caused by
PLTP expression by bone marrow derived cells. In addition, local
effects in the atherosclerotic lesion could contribute to this process.
These results indicate that the presence of PLTP in human
atherosclerotic lesions probably contributes to the pathologic
process and that inhibition of PLTP accumulation in atheroscle-
rotic lesions may be a valuable target for therapy.
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